Joint (JYNT) and Acacia Research (ACTG) Head to Head Survey

Joint (NASDAQ: JYNT) and Acacia Research (NASDAQ:ACTG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Risk & Volatility

How to Become a New Pot Stock Millionaire

Joint has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Acacia Research has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.

Valuation and Earnings

This table compares Joint and Acacia Research’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Joint $25.16 million 3.66 -$3.27 million ($0.25) -27.08
Acacia Research $65.40 million 2.71 $22.18 million $2.97 1.18

Acacia Research has higher revenue and earnings than Joint. Joint is trading at a lower price-to-earnings ratio than Acacia Research, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Joint and Acacia Research’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Joint -13.01% -66.74% -20.11%
Acacia Research 33.91% 50.06% 46.80%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Joint and Acacia Research, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Joint 0 0 4 0 3.00
Acacia Research 1 0 1 0 2.00

Joint presently has a consensus price target of $6.15, suggesting a potential downside of 9.16%. Acacia Research has a consensus price target of $6.50, suggesting a potential upside of 85.71%. Given Acacia Research’s higher possible upside, analysts plainly believe Acacia Research is more favorable than Joint.

Insider & Institutional Ownership

49.6% of Joint shares are held by institutional investors. Comparatively, 65.8% of Acacia Research shares are held by institutional investors. 6.1% of Joint shares are held by company insiders. Comparatively, 2.8% of Acacia Research shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Acacia Research beats Joint on 10 of the 14 factors compared between the two stocks.

Joint Company Profile

The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention. The Company has approximately 310 franchised, company-owned, or managed clinics in operation in over 30 states. In addition to its approximately 310 operating clinics, the Company has granted franchises either directly or through its regional developers for an additional over 170 clinics. The Company offers a range of membership and wellness packages. Each patient’s records are digitally updated for ready retrieval in its data storage system by its chiropractors in compliance with various applicable medical records security and privacy regulations.

Acacia Research Company Profile

Acacia Research Corporation, through its subsidiaries, invests in, licenses and enforces patented technologies. The Company’s operating subsidiaries partner with inventors and patent owners, applying their legal and technology expertise to patent assets to unlock the financial value in their patented inventions. The Company’s operating subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and, where necessary, with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation. The Company’s operating subsidiaries own or control the rights to multiple patent portfolios, which include the United States patents and certain foreign counterparts, covering technologies used in a range of industries.

Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

BNP Paribas Reiterates CHF 74 Price Target for Nestle
BNP Paribas Reiterates CHF 74 Price Target for Nestle
Roche  Given a CHF 230 Price Target at Morgan Stanley
Roche Given a CHF 230 Price Target at Morgan Stanley
Vermilion Energy  Price Target Raised to C$60.00 at Scotiabank
Vermilion Energy Price Target Raised to C$60.00 at Scotiabank
Spartan Energy  Downgraded by Raymond James to “Market Perform”
Spartan Energy Downgraded by Raymond James to “Market Perform”
Critical Survey: Match Group  versus Its Rivals
Critical Survey: Match Group versus Its Rivals
Financial Contrast: RPM International  and AkzoNobel
Financial Contrast: RPM International and AkzoNobel


Leave a Reply

© 2006-2018 Ticker Report. Google+.